Abstract：
Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is routinely prescribed as first-line therapy for advanced non-small cell lung cancer, regardless of the presence of the T790M resistance mutation. This study reports a rare case of Factor V inhibitor detection during osimertinib therapy in a patient with lung adenocarcinoma. These findings underscore the importance of vigilant monitoring for coagulation abnormalities during EGFR-TKI therapy.
摘要：
奥希替尼,第三代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI），常规处方作为晚期非小细胞肺癌的一线治疗，无论是否存在T790M抗性突变。本研究报告了一例罕见的肺腺癌患者在奥希替尼治疗期间检测到因子V抑制剂。这些发现强调了在EGFR-TKI治疗期间警惕监测凝血异常的重要性。
